Skip to main content
. 2011 Jun 27;2011:861401. doi: 10.1155/2011/861401

Table 4.

Issues discussed with patients before referral to Phase I trials? (single choice).

(1) Aims of Phase I (dose finding and toxicity) 25%
(2) Possibility of any clinical benefit 23%
(3) Chance of helping future cancer patients 17%
(4) Specific chance of response to Phase I 15%
(5) Risk of side effects 14%
(6) Specific drugs that could potentially help 3%
(7) Others ( Travel required ) 3%